The author congratulated Karl Deisseroth, Peter Hegemann and Georg Nagel on the 2026 Nobel Prize in Physiology or Medicine. They said Hegemann’s work had been supported by two ERC grants and a Horizon project, and wrote that Europe invested in frontier science that could transform the future. #NobelPrize #FrontierScience #MedicalResearch #EU
The author asked whether plasma proteins could help identify cardiovascular risk before symptoms appeared, writing that higher levels of haptoglobin and IgA2 were associated with increased risk of cardiovascular events and death, independently of traditional risk factors and imaging.
At @iaeaorg conference with ideas from 3700 participants from 181 countries România focused on: * Expansion of our nuclear plant facilities, with plans to double our current capacity in the years ahead * Medical research for children targeted cancer treatment with radioactive https://t.co/wEqV9KSonU #NuclearEnergy #MedicalResearch #Romania #RO
Breakthrough: Could Epstein–Barr virus (EBV) reactivation precede a multiple sclerosis relapse? EBV reactivation in B cells may be one component of the immune cascade preceding an MS relapse, particularly in individuals with the relevant genetic susceptibility - a finding that https://t.co/C6IvuoDkf1 #MultipleSclerosis #EBV #MedicalResearch #Thetweetdoesnotspecificallymentionanycountries.Therefore #therearenocountrycodestoreturn.
In nationwide 🇸🇪 study of 14,801 patients with fatty liver (MASLD), we saw a +54% ⬆️ increased risk of peripheral arterial disease. Risk generally increased with histologic severity. Kudos to [1au] @Yuan_AS at @Penn and co-authors 🙏 @damrauer @jiangwei_sun @karolinskainst et al #FattyLiver #PeripheralArterialDisease #MedicalResearch #SE
"Nearly 7 years after her first attempt to test Ebola prevention drugs, Jaspard is stunned by the sudden interest in the trial. “I've kept this project for all these years, despite the fact that a lot of people were saying it's not useful, you don't need to do this, go away,” she #Ebola #ClinicalTrials #MedicalResearch #Therearenospecificcountryreferencesinthetweetprovided.
One glimmer of hope in the Ebola response: Within hours of the outbreak in DRC being declared, researchers convened to prepare drug trials. A lot has changed on that front since the Ebola outbreak in West Africa a decade ago. But huge challenges remain… My story in #Ebola #DRC #MedicalResearch #CD #GW
Maria Patzwald, a 38-year-old woman diagnosed with severe preeclampsia during her second pregnancy, participated in a pioneering clinical trial that targeted a specific protein believed to cause the condition, leading to a significant extension of her pregnancy by 10 days and an increased survival chance for her premature son. #Pregnancy #Preeclampsia #MedicalResearch #US #DE #GB
A 38-year-old woman named Maria Patzwald participated in a pioneering trial aimed at treating preeclampsia, a potentially fatal pregnancy complication, and her involvement helped extend her son's gestation by two weeks, significantly improving his chances of survival. #PregnancyCare #MedicalResearch #PreEclampsia #US #DE #GB
A 38-year-old woman, Maria Patzwald, participated in a pioneering trial for treating preeclampsia, a serious pregnancy complication, which helped extend her pregnancy by ten days, allowing her son Bennet to be born at 34 weeks, significantly improving his chances of a healthy outcome. #Pregnancy #Preeclampsia #MedicalResearch #US #DE #GB
The Wound Innovation Institute in Hull, a new £48m research facility, aims to transform the treatment of chronic wounds by bringing together researchers, NHS clinicians, and industry partners to develop innovative therapies, addressing a significant clinical need that costs the NHS £8.3bn annually. #WoundCare #MedicalResearch #Innovation #GB
The newly opened £48 million Wound Innovation Institute in Hull aims to revolutionize treatment for chronic wounds by uniting researchers, NHS clinicians, and industry partners to develop innovative therapies, addressing a critical clinical need that costs the NHS £8.3 billion annually. #WoundCare #MedicalResearch #HealthcareInnovation #GB
The newly established £48 million Wound Innovation Institute in Hull aims to revolutionize the treatment of chronic wounds by collaborating with academics, NHS clinicians, and industry partners to research their causes and develop innovative therapies, with significant funding support from both private companies and government grants. #WoundCare #MedicalResearch #HealthcareInnovation #GB
The Wound Innovation Institute at the University of Hull, supported by £48m in funding, aims to revolutionize the treatment of chronic wounds through research collaborations that promise to significantly improve patient outcomes and reduce NHS costs. #WoundCare #MedicalResearch #HealthcareInnovation #GB
The newly opened £48m Wound Innovation Institute in Hull aims to transform the treatment of chronic wounds by collaborating with academics, NHS clinicians, and industry partners to develop innovative therapies and advance research in the field, addressing a significant area of unmet clinical need. #WoundCare #MedicalResearch #HealthcareInnovation #GB
The newly opened £48m Wound Innovation Institute in Hull aims to transform the treatment of chronic wounds by collaborating with academics, NHS clinicians, and industry partners to develop innovative therapies and advance research in the field, addressing a significant area of unmet clinical need. #WoundCare #MedicalResearch #HealthcareInnovation #GB
Oltre all'adenocarcinoma del pancreas, qual è l'altro tumore maledetto, che mi ha pure portato via persone carissime? Il glioblastoma. E io che devo a stare a parlare del virus Andes mentre la scienza fa i primi passi anche contro questo assassino! https://t.co/LLDy8vpyZq #Glioblastoma #CancerAwareness #MedicalResearch #IT #AR
An international consortium has renamed polycystic ovary syndrome (P.C.O.S.) to polyendocrine metabolic ovarian syndrome (P.M.O.S.) to more accurately reflect its complex hormonal and metabolic effects, aiming to improve diagnosis, treatment, and funding for the condition, which affects 10-13% of reproductive-age women. #WomensHealth #EndocrineDisorders #MedicalResearch #AU #US
In a significant breakthrough for pancreatic cancer treatment, the experimental drug daraxonrasib has shown promise in prolonging patient survival by targeting a previously deemed untreatable protein, KRAS, marking a potential turning point in the battle against this deadly disease after decades of failed treatments and research. #PancreaticCancer #MedicalResearch #CancerTreatment #US #CA
